Understanding Starter Doses: Wegovy vs Mounjaro Differences
Ozempic, Wegovy, and Mounjaro: Starter Dose Fundamentals
When comparing Ozempic, Wegovy, and Mounjaro starter doses, it's essential to understand their distinct licensing and dosing protocols. Wegovy begins with a 0.25mg starter dose for weeks 1-4, designed to minimise initial side effects whilst allowing your body to adapt to semaglutide. Mounjaro starts at 2.5mg tirzepatide weekly, representing a different approach with its dual hormone mechanism. Ozempic, whilst containing the same semaglutide as Wegovy, is exclusively licensed for type 2 diabetes and should not be considered for weight management purposes.
The starter dose phase is crucial for long-term success with either Wegovy or Mounjaro. During this initial period, patients typically experience the first appetite changes and may notice reduced food cravings. Your prescriber will determine which medication and starting approach aligns best with your medical history, current medications, and weight management goals. Both options require careful medical supervision and cannot be obtained without a valid prescription from a qualified healthcare professional.
Wegovy and Mounjaro Starter Dose Pricing Comparison
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro starter doses, with Wegovy 0.25mg available for £79.99 and comprehensive bundle options for extended treatment phases. Our Intro Duo bundle combines the 0.25mg starter with the 0.5mg second-phase dose for £169.99, providing seamless progression through your first two months. New customers benefit from the FIRST40 discount code applied at checkout, whilst returning customers can use DOSE25 for ongoing savings.
Mounjaro pricing follows a different structure due to its distinct dosing schedule, with the 2.5mg starter dose priced competitively within the weight management market. Both medications represent significant investments in your health, supported by extensive clinical evidence and regulatory approval. Payment is processed securely through our platform, with cold-chain delivery ensuring medication integrity from our GPhC-registered pharmacy (#9012878) directly to your door within 24 hours of prescription approval.
Clinical Evidence: Wegovy vs Mounjaro Starter Dose Efficacy
Clinical trials demonstrate that proper starter dose protocols are essential for both Wegovy and Mounjaro effectiveness. In the STEP 1 trial, patients following the Wegovy escalation schedule beginning with 0.25mg achieved approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). The gradual dose escalation starting from this low dose helped minimise discontinuation due to side effects.
Mounjaro's clinical programme, including the SURMOUNT trials, showed that patients beginning with the 2.5mg starter dose and following the tirzepatide escalation protocol achieved significant weight reductions when treatment was combined with a reduced-calorie diet and increased physical activity. However, different trial designs, populations, and endpoints mean direct comparison of percentage weight loss between these medications cannot be made accurately.
How Wegovy Works: GLP-1 Mechanism from Starter Dose
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone responsible for blood sugar regulation and appetite control. From the very first 0.25mg starter dose, semaglutide begins binding to GLP-1 receptors in your brain's appetite centres, gradually reducing hunger signals and promoting earlier satiety during meals. This mechanism helps patients naturally consume smaller portions without the constant struggle against cravings that characterises traditional calorie restriction approaches. The medication also slows gastric emptying, meaning food remains in your stomach longer, contributing to prolonged feelings of fullness. Unlike Ozempic (which contains the same semaglutide but is licensed only for diabetes), Wegovy is specifically formulated and dosed for weight management in adults with obesity or overweight with comorbidities.
EverydayMeds Ordering Process: From Assessment to Delivery
Starting your Wegovy journey through EverydayMeds begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any contraindications to semaglutide therapy. Our qualified prescribers review each application individually, typically within 3 working days (or 24 hours with our express service), ensuring safe and appropriate prescribing aligned with MHRA guidelines and NICE recommendations. Once approved, your medication is dispatched via temperature-controlled courier service, maintaining the cold chain integrity essential for semaglutide stability. Our packaging includes ice packs and temperature monitoring to ensure your Wegovy arrives in optimal condition. All orders are tracked, and our clinical team remains available for ongoing support throughout your treatment journey with this prescription-only medicine.
Wegovy Storage and Practical Considerations
Proper storage begins immediately with your starter dose, as Wegovy requires refrigeration at 2-8°C before first use to maintain medication potency and safety. Once removed from refrigeration, Wegovy can be stored at room temperature (below 30°C) for up to 6 weeks, providing significantly more flexibility than Mounjaro's 21-day room temperature limit. The FlexTouch pen design makes weekly injections straightforward, with clear dose indicators and safety features to prevent accidental double-dosing. Each pen contains 4 weekly doses, meaning your 0.25mg starter pen will last exactly one month before progressing to the 0.5mg dose. The mandatory dose escalation schedule cannot be accelerated or skipped, as this increases the risk of gastrointestinal side effects and may compromise treatment effectiveness.
First Month Expectations: Ozempic vs Wegovy vs Mounjaro Starter Experience
During your first month on Wegovy's 0.25mg starter dose, most patients notice gradual appetite changes rather than dramatic immediate effects, which is precisely the intended gentle introduction to semaglutide therapy. Some individuals experience mild nausea, particularly after larger meals, which typically resolves as your body adapts to the medication's gastric emptying effects. This contrasts with Mounjaro's 2.5mg starting dose, which may produce more noticeable initial effects due to its dual GIP+GLP-1 mechanism targeting multiple pathways simultaneously.
It's crucial to remember that Ozempic, despite containing semaglutide, should never be considered for weight management as it's exclusively licensed for type 2 diabetes treatment. The starter dose experience varies significantly between individuals, with some patients noticing reduced food cravings within the first week, whilst others require several weeks to observe meaningful appetite changes. Maintaining realistic expectations during this initial phase is essential, as the most significant benefits typically emerge during the dose escalation process over months 2-4 of treatment.
Secure Your Wegovy Starter Dose Today
EverydayMeds makes beginning your weight management journey with Wegovy straightforward and secure, with our 0.25mg starter dose available for £79.99 and multiple bundle options to support your progression through the complete escalation schedule. New customers should apply discount code FIRST40 at checkout, whilst returning customers benefit from DOSE25 for ongoing savings on subsequent orders. Our clinical team, operating under GPhC registration #9012878, ensures every prescription meets the highest safety standards whilst providing the support you need for successful long-term weight management. Both Wegovy and Mounjaro are available through our platform, and your prescriber will help determine which option aligns best with your individual circumstances. Complete your clinical assessment today to begin this transformative journey with expert medical guidance every step of the way.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
